DLL3 and small cell lung carcinoma: Rudin et al. (2017) demonstrated the potential of Rova-T (rovalpituzumab teserine), which specifically targets Delta-like canonical Notch ligand 3 (DLL3), a unique biomarker of SCLC (Rudin et al., 2017). Overexpression of DLL3, an inhibitor of the Notch signaling pathway, has fueled interest in targeting this ligand for drug development, resulting in the exploration of agents like Rova-T, AMG 757, AMG 119, DLL3-targeted bispecific antibodies, and CAR-modified T cells (Owonikoko et al., 2020; Byers et al., 2019).